Abstract
Novel triazoloquinazolines have been found as phosphodiesterase 10A (PDE10A) inhibitors. Structure-activity studies improved the initial micromolar potency which was found in the lead compound by a 100-fold identifying 5-(1H-benzoimidazol-2-ylmethylsulfanyl)-2-methyl-[1,2,4]triazolo[1,5-c]quinazoline, 42 (PDE10A IC(50)=12 nM) as the most potent compound from the series. Two X-ray structures revealed novel binding modes to the catalytic site of the PDE10A enzyme.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Benzimidazoles / chemical synthesis*
-
Benzimidazoles / chemistry
-
Benzimidazoles / pharmacology*
-
Crystallography, X-Ray
-
Enzyme Activation / drug effects
-
Inhibitory Concentration 50
-
Models, Molecular
-
Molecular Structure
-
Phosphodiesterase Inhibitors / chemical synthesis*
-
Phosphodiesterase Inhibitors / chemistry
-
Phosphodiesterase Inhibitors / pharmacology
-
Phosphoric Diester Hydrolases / metabolism*
-
Protein Binding
-
Quinazolines / chemical synthesis*
-
Quinazolines / chemistry
-
Quinazolines / pharmacology*
-
Rats
Substances
-
5-(1H-benzoimidazol-2-ylmethylsulfanyl)-2-methyl(1,2,4)triazolo(1,5-c)quinazoline
-
Benzimidazoles
-
Phosphodiesterase Inhibitors
-
Quinazolines
-
PDE10A protein, human
-
Phosphoric Diester Hydrolases